Etoricoxib Use in Anemic Patients: Critical Safety Concerns and Clinical Decision Algorithm

Cardiovascular and Renal Risks

The American Heart Association warns that COX-2 inhibitors like etoricoxib suppress prostacyclin production while leaving platelet thromboxane A2 intact, creating a prothrombotic state that is particularly dangerous in anemic patients with reduced oxygen-carrying capacity 1
Etoricoxib increases cardiovascular thrombotic events similarly to diclofenac (hazard ratio 1.02, 95% CI 0.87-1.18), which is concerning because anemic patients already have compromised oxygen delivery 1
Naproxen may be preferable to etoricoxib in patients with cardiovascular risk factors, though it still carries GI bleeding risk 1

Before considering etoricoxib, obtain complete blood count with reticulocyte count, iron studies (ferritin, transferrin saturation), vitamin B12, folate, and peripheral blood smear to identify the cause of anemia 2, 3
All causes of anemia must be corrected before considering etoricoxib 2, 3
For iron deficiency with ferritin <100 ng/mL and transferrin saturation <20%, administer IV iron (ferric carboxymaltose or iron isomaltoside) to achieve ferritin >100 ng/mL and transferrin saturation >20% 4
Expect hemoglobin to increase by ≥1 g/dL within 4 weeks of IV iron repletion before considering any NSAID therapy 4

Absolute contraindication: Active GI bleeding, history of immune hemolytic anemia, unexplained anemia, hemoglobin <8 g/dL 2

Avoid combining etoricoxib with aspirin, as this negates the GI safety advantage while maintaining cardiovascular risk 1